WS #15279
Tesla ($TSLA) shares rose 5% after Q3 deliveries beat production estimates, marking the first sales increase in two years and signaling a potential turnaround in the EV market. In healthcare, Eli Lilly ($LLY) received FDA approval for Jaypirca as a first-line treatment for CLL/SLL, a significant milestone for its oncology portfolio. These company-specific catalysts are driving outperformance in their respective sectors, decoupling from broader macro trends.
Corporate: Tesla Turnaround and Eli Lilly FDA Win
Tesla ($TSLA) shares rose 5% after Q3 deliveries beat production estimates, marking the first sales increase in two years and signaling a potential turnaround in the EV market. In healthcare, Eli Lilly ($LLY) received FDA approval for Jaypirca as a first-line treatment for CLL/SLL, a significant milestone for its oncology portfolio. These company-specific catalysts are driving outperformance in their respective sectors, decoupling from broader macro trends.